Arix Bioscience PLC (ARIX) Arix Bioscience PLC: Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021 13-Dec-2021 / 15:50 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Arix Bioscience plc

Autolus Therapeutics presents positive obe-cel data at the American Society of Hematology (ASH) Annual Meeting 2021

LONDON, UK, 13 December 2021: Arix Bioscience plc ("Arix", LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Autolus Therapeutics plc (Nasdaq: AUTL), today announced the presentation of new data on obe-cel (AUTO1) and AUTO1/22 at the American Society of Hematology (ASH) Annual Meeting, being held between December 11-14, 2021.

At the meeting, Autolus reported the following:

-- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19study

-- Obe-cel response and safety data from the Phase 1b portion of the FELIX study consistent with the Phase 1ALLCAR19 study

-- Obe-cel achieves a metabolic CR in 100% patients with FL, MCL and DLBCL, with long term persistenceevident and without ICANS or high grade CRS

-- Dual targeting AUTO1/22 shows data consistent with high level of activity and good engraftment

Autolus management held a conference call and webcast earlier today at 8:00 am ET/1:00 pm GMT to discuss the ASH data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus' website https://www.autolus.com/

Full text of the announcement from Autolus is contained below and can also be accessed on Autolus' website.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil

+44 (0)20 7250 1446

arix@powerscourt-group.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks o help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

AUTOLUS PRESS RELEASE

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

-- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19study

-- Obe-cel response and safety data from the Phase 1b portion of the FELIX study consistent with the Phase 1ALLCAR19 study

-- Obe-cel achieves a metabolic CR in 100% patients with FL, MCL and DLBCL, with long term persistenceevident and without ICANS or high grade CRS

-- Dual targeting AUTO1/22 shows data consistent with high level of activity and good engraftment

Conference Call and Webcast to be held Monday, Dec 13, 2021 at 8:00 am ET / 1:00 pm GMT

LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled "Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process" at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. The Company also presented an update of obe-cel in relapsed/refractory aggressive and indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL) patients from the ALLCAR19 extension study, as well as preclinical and initial engraftment data with AUTO1/22 in Pediatric ALL in two separate poster presentations [Abstracts 3823 and 1710, respectively].

"We continue to observe sustained responses with obe-cel, with an EFS of 46% at 24 months and patients approaching up to 42 months of durability in the ALLCAR-19 study, supporting the curative potential of obe-cel as a standalone therapy in r/r B-ALL patients. Furthermore, we were encouraged to observe comparable safety and high complete response data between patients treated in the academic ALLCAR19 study and those in the Phase 1b portion of the Autolus sponsored FELIX study," said Dr. Christian Itin, chief executive officer of Autolus. "In addition, we are excited to observe further positive data for obe-cel in r/r B-NHL and B-CLL patients, as well as compelling initial data for AUTO1/22, pointing to the potential for indication expansion and life cycle management opportunities longer term."

Obe-cel in Adult Acute Lymphoblastic Leukemia patients (FELIX study) Oral Presentation Title: Industrialization of an Academic Miltenyi Prodigy-Based CAR T process Session Name: 711. Cell Collection and Processing: Advances in Mobilization, Collection, Manipulation and Engineering of HSCs and T Cells Abstract: #477 Date: Sunday, December 12, 2021 Session Time: 12:00 PM - 1:30 PM ET; Presentation Time: 12:30 PM ET Location: Georgia World Congress Center, Hall A1 Presenter: Dr. Claire Roddie, MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)

Initial experience in the phase 1b portion of the FELIX 1b/2 study (NCT04404660) resulted comparable results as seen in the Phase 1 ALLCAR19 study. As of the cut-off date of 13 September, 16 patients in the Phase 1b part of the FELIX study had received obe-cel. Patient characteristics in the FELIX 1b portion were broadly comparable to those observed in the ALLCAR19 study in r/r adult B-ALL.

-- As of the data cut off date of 15 October 2021, ALLCAR19 data shows morphological EFS for obe-cel is 46%at 24 months with a median follow-up of 29.3 months and patients approaching up to 42 months of durability.

-- Baseline characteristics between FELIX Phase 1b and ALLCAR19 studies are similar. 75% patients in theFELIX Phase 1b had >20% blasts at pre-conditioning, compared with 60% patients in ALLCAR19. 56.3% patients receivedprior blinatumomab in the FELIX Phase 1b study compared with 25% in ALLCAR191.

-- High level of CR/CRi response rate at 1 month observed across both studies, with 12/16 patients in theFELIX Phase 1b study, consistent with 17/201 patients in the ALLCAR19 study.

-- Safety consistent between the ALLCAR19 study and FELIX Phase 1b study, with no patient having high grade(>=Grade 3) cytokine release syndrome (CRS). 1 of 16 patients experienced a Grade 3 immune effector cell-associatedneurotoxicity syndrome (ICANS) in the FELIX Phase 1b study, as compared with 3 of 20 patients in ALLCAR-19 study1.

The company expects to present data from the Phase 2 portion of the FELIX study in 2022.

1 Roddie et al. "Durable responses and low toxicity after fast off-rate CD19 CAR-T therapy in adults with relapsed/ refractory B-ALL." DOI: 10.1200/JCO.21.00917 Journal of Clinical Oncology - published online before print August 31, 2021

Obe-cel (AUTO1) in Adult Acute Lymphoblastic Leukemia patients (ALLCAR study) Poster Presentation Title: Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL) Session Title: 704. Cellular Immunotherapies: Clinical: Poster III Abstract: #3823 Date: Monday, December 13, 2021 Presentation Time: 6:00 PM - 8:00 PM ET Location: Georgia World Congress Center, Hall B5 Presenter: Dr. Claire Roddie, MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)

As of the data cut-off date of October 15, 2021, 15 r/r B-NHL and 1 B-CLL patient had received obe-cel with 14 patients evaluable for response.

-- 14 of 14 patients responded to obe-cel of which 13 of 14 patients achieved complete metabolic responseper Lugano 2014, with 1 B-CLL patient in PR.

-- 15 of 16 patients were without disease progression at last follow-up, with 1 of 16 patients having diedin CR from COVID-19. Furthermore, long term persistence was demonstrated by qPCR.

-- Median follow up time for Follicular Lymphoma (FL) and DLBCL patients was 11.8 months (range 2-14.2m).

-- Median follow up time for Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma patients was 7.4months (range 1.1-14.8m).

-- Across all patients, obe-cel demonstrated a favorable safety profile with no ICANS or severe Grade >= 3CRS events.

The company expects to present further data from more B-NHL and CLL patients in H1 2022.

AUTO1/22 in Pediatric Acute Lymphoblastic Leukemia patients (CARPALL) Poster Presentation Title: A high sensitivity aCD22 CAR combined with aCD19 CAR to generate dual targeting CAR T cells for the treatment of r/r B-ALL Session Title: 703. Cellular Immunotherapies: Basic and Translational: Poster I Abstract: #1710 Date: Saturday, December 11, 2021 Presentation Time: 5:30 PM - 7:30 PM ET Location: Georgia World Congress Center, Hall B5 Presenter: Dr. Sara Ghorashian, MD, PhD, Hon clinical senior lecturer, UCL Great Ormond Street Institute of Child Health

(MORE TO FOLLOW) Dow Jones Newswires

December 13, 2021 10:51 ET (15:51 GMT)

Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Arix Bioscience Charts.
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Arix Bioscience Charts.